A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of brain disorders, like Alzheimer’s disease and Parkinson’s disease.

2024-520142-32-00 Protocol NT-0150-P001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 8 Sep 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol NT-0150-P001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 53
Countries 1
Sites 1

Cryopyrin associated periodic syndrome

Key facts

Sponsor
Nodthera Limited
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
8 Sep 2025 → ongoing
Decision date (initial)
2025-09-05
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Cryopyrin associated periodic syndrome

VersionLevelCodeTermSystem organ class
27.0 PT 10068850 Cryopyrin associated periodic syndrome 100000004850

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Nodthera Limited

2 Total trials 2 Ended
Commercial
Sponsor organisation
Nodthera Limited
Address
13 Queens Road
City
Aberdeen
Postcode
AB15 4YL
Country
United Kingdom

Scientific contact point

Organisation
Nodthera Limited
Contact name
Nick Clarke

Public contact point

Organisation
Nodthera Limited
Contact name
Nick Clarke

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruitment ended 53 1
Rest of world — 0 —

Investigational sites

Netherlands

1 site · Ongoing, recruitment ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-09-08 2025-09-08 2026-05-26

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-14 Netherlands Acceptable
2025-09-05
 2025-09-05